Private Equity Profile
In the last 3 years, Ampersand Capital Partners has acquired 7 companies. It has also invested in 10 others.
Ampersand Capital Partners’ most common sectors for investment are life science (49%) and medical products (25%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (33%) and growth capital (30%). In total, Ampersand Capital Partners has invested in 20 US states and 5 different countries. Its largest (disclosed) acquisition occurred in 2013 when it acquired BioClinica for $123M.
In the last 3 years, Ampersand Capital Partners has exited 9 companies. The Firm’s most common exit type is trade sale (72%). Ampersand Capital Partners’ largest (disclosed) exit occurred in 2008 when it sold Talecris Biotherapeutics Holdings Corp for $3.1B.
Join Mergr to view Ampersand Capital Partners’ full profile and discover more large private equity firms just like it.
M&A Total Activity100
- M&A Buy Activity58
- M&A Sell Activity42
- Total Sectors Invested 12
- Total Countries Invested 5
- M&A Buy/Sell Connections 53
- M&A Advisors 1